Maze Therapeutics' Atul Dandekar sells 7,500 shares

Q: How many MAZE shares did Atul Dandekar sell, and at what price?

Atul Dandekar sold 7,500 common shares on October 29, 2026, at a weighted average price of $32.0709 per share. The reported sale prices ranged from $31.61 to $32.56 per share, and the sale was under a Rule 10b5-1 plan adopted September 29, 2025.

The CSBO's reported transactions were under a Rule 10b5-1 plan adopted September 29, 2025.

Available on EDGAR 10/30/2026 - 04:15 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:14 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Maze Therapeutics, Inc. CSBO Atul Dandekar exercised options covering 6,643 and 857 shares on October 29, 2026, each at an exercise price of $10.42 per share, acquiring the corresponding common shares. The options expire April 11, 2031, and April 23, 2034, respectively. He sold 7,500 common shares that day at a weighted average price of $32.0709 per share; the reported sale prices ranged from $31.61 to $32.56 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted September 29, 2025. The 6,643-share option was fully vested on March 17, 2025; the 857-share option vests in monthly 1/48th tranches, subject to continued service.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($162K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Dandekar Atul

Role CSBO

Sold 7,500 shs ($241K)

Approx. gross sale proceeds $241K

Approx. exercise cost $78K

Approx. pre-tax spread $162K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F3}	6,643	$0.00	$0.00
Exercise	Stock Option (Right to Buy) ^{F1, F4}	857	$0.00	$0.00
Exercise	Common Stock ^F1	6,643	$10.42	$69K
Exercise	Common Stock ^F1	857	$10.42	$9K
Sale	Common Stock ^{F1, F2}	7,500	$32.0709	$241K

Holdings After Transaction: Stock Option (Right to Buy) — 25,073 contracts (Direct); Common Stock — 32,316 shares (Direct)

Footnotes (4)

F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.61 to $32.56 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
F4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Key Figures

Options exercised: 6,643 shares Options exercised: 857 shares Exercise price: $10.42 per share +3 more

6 metrics

Options exercised 6,643 shares Option expiring April 11, 2031; October 29, 2026

Options exercised 857 shares Option expiring April 23, 2034; October 29, 2026

Exercise price $10.42 per share Options exercised October 29, 2026

Shares sold 7,500 shares October 29, 2026

Weighted average sale price $32.0709 per share October 29, 2026

Reported sale price range $31.61 to $32.56 per share October 29, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested, vesting

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested financial

"The option is fully vested"

vesting financial

"vesting as to 1/48th of the total award monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MAZE shares did Atul Dandekar sell, and at what price?

Atul Dandekar sold 7,500 common shares on October 29, 2026, at a weighted average price of $32.0709 per share. The reported sale prices ranged from $31.61 to $32.56 per share, and the sale was under a Rule 10b5-1 plan adopted September 29, 2025.

What MAZE options did Atul Dandekar exercise?

Atul Dandekar exercised options covering 6,643 and 857 shares on October 29, 2026, each at an exercise price of $10.42 per share. The options expire April 11, 2031, and April 23, 2034, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CSBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/29/2026		M⁽¹⁾		6,643	A	$10.42	38,959	D
Common Stock	10/29/2026		M⁽¹⁾		857	A	$10.42	39,816	D
Common Stock	10/29/2026		S⁽¹⁾		7,500	D	$32.0709⁽²⁾	32,316	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$10.42	10/29/2026		M⁽¹⁾			6,643	⁽³⁾	04/11/2031	Common Stock	6,643	$0	0	D
Stock Option (Right to Buy)	$10.42	10/29/2026		M⁽¹⁾			857	⁽⁴⁾	04/23/2034	Common Stock	857	$0	25,073	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.61 to $32.56 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR